Meiji Holdings Co., Ltd. Meiji Holdings Co., Ltd. Financial Results - For the FYE March 2017 -  


Pharma: Decreased Income - NHI Price Revisions and Increased Expenses, Despite Promotion of Newly Launched Products

Prev. Page Next Page Download the PDF
Pharmaceuticals segment: Operating income JPY 5.7 billion

 • YoY decrease of JPY 4.3 billion
Increased sales of newly launched drugs such as Sycrest and Bilanoa
Increased sales volume of generics
Impacted by NHI price revisions, one-time license fee payments and increase in promotion expenses

 • Increased by JPY 0.7 billion compared to revised plan released in February 2017
Company-wide cost control
Receipt of one-time contract payments

Licensed Safinamide, drug for Parkinson's Disease, to Eisai Co., Ltd.